oncolytic virus

oncolytic virus (Mianyang Central Hospital) refers to an investigational oncolytic viral agent being evaluated in a Phase 1/2 clinical trial (NCT05371002) for the treatment of recurrent glioblastoma. Developed and sponsored by Mianyang Central Hospital, the therapy involves the intratumoral injection of the virus directly into the brain tumor. The mechanism of action for oncolytic viruses typically involves two prongs: the direct lysis of tumor cells through selective viral replication and the subsequent induction of a systemic anti-tumor immune response triggered by the release of tumor antigens and inflammatory cytokines. This trial specifically assesses the safety, tolerability, and preliminary efficacy of the agent in patients who have failed standard-of-care treatments for glioblastoma.

Other names

oncolytic virus